0.000
0.00 (0.00%)
| Harga / Jualan (P/S) | 7.61 |
| Harga / Buku (P/B) | 1.48 |
| Margin Operasi (TTM) | -476.01% |
| EPS Cair (TTM) | -5.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 78.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.89% |
| Nisbah Semasa (MRQ) | 9.13 |
| Aliran Tunai Operasi (OCF TTM) | -311.09 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -179.04 M |
| Pulangan Atas Aset (ROA TTM) | -36.35% |
| Pulangan Atas Ekuiti (ROE TTM) | -63.53% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Sage Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | 1.25 |
|
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.41% |
| % Dimiliki oleh Institusi | 83.79% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |